Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
CNS Neurosci Ther ; 23(2): 162-173, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27943591

RESUMO

INTRODUCTION: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most prevalent cause of familial and sporadic Parkinson's disease (PD). Because most pathogenic LRRK2 mutations result in enhanced kinase activity, it suggests that LRRK2 inhibitors may serve as a potential treatment for PD. To evaluate whether LRRK2 inhibitors are effective therapies for PD, it is crucial to know whether LRRK2 inhibitors will affect dopaminergic (DAergic) neurotransmission. However, to date, there is no study to investigate the impact of LRRK2 inhibitors on DAergic neurotransmission. AIMS: To address this gap in knowledge, we examined the effects of three types of LRRK2 inhibitors (LRRK2-IN-1, GSK2578215A, and GNE-7915) on dopamine (DA) release in the dorsal striatum using fast-scan cyclic voltammetry and DA neuron firing in the substantia nigra pars compacta (SNpc) using patch clamp in mouse brain slices. RESULTS: We found that LRRK2-IN-1 at a concentration higher than 1 µM causes off-target effects and decreases DA release, whereas GSK2578215A and GNE-7915 do not. All three inhibitors at 1 µM have no effect on DA release and DA neuron firing rate. We have further assessed the effects of the inhibitors in two preclinical LRRK2 mouse models (i.e., BAC transgenic hG2019S and hR1441G) and demonstrated that GNE-7915 enhances DA release and synaptic vesicle mobilization/recycling. CONCLUSION: GNE-7915 can be validated for further therapeutic development for PD.


Assuntos
Corpo Estriado/citologia , Dopamina/metabolismo , Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina/metabolismo , Doença de Parkinson/patologia , Substância Negra/citologia , Aminopiridinas/farmacologia , Animais , Benzamidas/farmacologia , Benzodiazepinonas/farmacologia , Fenômenos Biofísicos/efeitos dos fármacos , Fenômenos Biofísicos/genética , Corpo Estriado/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Estimulação Elétrica , Técnicas In Vitro , Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina/genética , Masculino , Camundongos , Camundongos Transgênicos , Morfolinas/farmacologia , Mutação/genética , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/genética , Técnicas de Patch-Clamp , Pirimidinas/farmacologia , Substância Negra/efeitos dos fármacos
2.
Yi Chuan ; 29(1): 3-7, 2007 Jan.
Artigo em Chinês | MEDLINE | ID: mdl-17284416

RESUMO

Case-control studies, which serve as standard design for genetic association analysis, can be the most practical and powerful approach to detect genetic polymorphisms contributing to susceptibility to complex human diseases. However, considerable concern has been expressed that this approach is prone to population stratification, which can lead to biased or spurious results. We review several methods to detect and account for population stratification; these methods include nuclear family-based transmission/disequilibrium test (TDT), and genomic control (GC) and structured association (SA) based on unlinked genetic markers.


Assuntos
Estudos de Casos e Controles , Predisposição Genética para Doença/genética , Estudo de Associação Genômica Ampla/métodos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA